Tag: nivolumab approval
Bristol Myers Squibb Secures Dual Regulatory Wins for Opdivo® in Classical Hodgkin Lymphoma
Bristol Myers Squibb (NYSE: BMY) announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and...